Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr;80(4):432-439.
doi: 10.1136/annrheumdis-2020-218412. Epub 2020 Nov 4.

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

Affiliations
Clinical Trial

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

Roy M Fleischmann et al. Ann Rheum Dis. 2021 Apr.

Abstract

Objectives: To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis with non-response or incomplete-response to the initial therapy.

Methods: SELECT-COMPARE randomised patients to upadacitinib 15 mg once daily (n=651), placebo (n=651) or adalimumab 40 mg every other week (n=327). A treat-to-target study design was implemented, with blinded rescue occurring prior to week 26 for patients who did not achieve at least 20% improvement in both tender and swollen joint counts ('non-responders') and at week 26 based on Clinical Disease Activity Index (CDAI) >10 ('incomplete-responders') without washout.

Results: A total of 39% (252/651) and 49% (159/327) of patients originally randomised to upadacitinib and adalimumab were rescued to the alternate therapy. In both switch groups (adalimumab to upadacitinib and vice versa) and in non-responders and incomplete-responders, improvements in disease activity were observed at 3 and 6 months following rescue. CDAI low disease activity was achieved by 36% and 47% of non-responders and 45% and 58% of incomplete-responders switched to adalimumab and upadacitinib, respectively, 6 months following switch. Overall, approximately 5% of rescued patients experienced worsening in disease activity at 6 months postswitch. The frequency of adverse events was similar between switch groups.

Conclusions: These observations support a treat-to-target strategy, in which patients who fail to respond initially (or do not achieve sufficient response) are switched to a therapy with an alternate mechanism of action and experience improved outcomes. No new safety findings were observed despite immediate switch without washout.

Trial registration: ClinicalTrials.gov NCT02629159.

Keywords: adalimumab; arthritis; health care; outcome assessment; rheumatoid; therapeutics; tumor necrosis factor inhibitors.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RMF has received grant/research support from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD-Serono, Genentech, Gilead, Janssen, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi-Aventis, UCB and Viela and is a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis and UCB. RB has received grants/research support from AbbVie, MSD and Roche and had consultation fees/participation in company-sponsored speaker’s bureau from AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Pfizer, and Roche. SH has received research grants and consultancy fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer and UCB. GTDT has received a research grant from AbbVie and consulting fees from Amgen. FEVdB has received speaker and/or consultancy fees from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Janssen, Merck, Novartis, Pfizer and UCB. CZ has received grants/research support from AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer and Sanofi. LB has received grant/research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis and UCB and is a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, Janssen, Novartis, Pfizer Inc, Sanofi-Aventis and UCB. JE, YL, YS, RD and I-HS are full-time employees of AbbVie and may hold AbbVie stock or stock options.

Figures

Figure 1
Figure 1
Proportion of patients rescued. *12% (78/651), 5% (29/651) and 3% (19/651) of patients were rescued from UPA to ADA at W14, W18 and W22, respectively. 17% (56/327), 4% (14/327) and 2% (7/327) were rescued from ADA to UPA at W14, W18 and W22, respectively. ADA, adalimumab; CDAI, Clinical Disease Activity Index; LDA, low disease activity; SJC66, swollen joint count-66 joints; TJC68, tender joint count-68 joints; UPA, upadacitinib; W, week.
Figure 2
Figure 2
Percentage of non-responders (A) and incomplete-responders (B) achieving ACR20/50/70 at 3 and 6 months postswitch. All data points are provided in online supplemental table S6. ACR20/50/70, improvement of at least 20%, 50% and 70% in American College of Rheumatology criteria from baseline; ADA, adalimumab; mo, month; UPA, upadacitinib.
Figure 3
Figure 3
Percentage of non-responders and incomplete-responders achieving CDAI LDA (A) and remission (B), and DAS28(CRP)≤3.2 (C) and <2.6 (D) at 3 and 6 months postswitch. All data points are provided in online supplemental table S7. ADA, adalimumab; CDAI, Clinical Disease Activity Index; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; LDA, low disease activity; UPA, upadacitinib.
Figure 4
Figure 4
Percentage of non-responders and incomplete-responders with DAS28(CRP) change from switch >0.6 (A) and >1.2 (B). ADA, adalimumab; DAS28(CRP), 28-joint Disease Activity Score based on C-reactive protein; UPA, upadacitinib.

References

    1. Smolen JS, Breedveld FC, Burmester GR, et al. . Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international Task force. Ann Rheum Dis 2016;75:3–15. 10.1136/annrheumdis-2015-207524 - DOI - PMC - PubMed
    1. Singh JA, Saag KG, Bridges SL, et al. . 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1–26. 10.1002/art.39480 - DOI - PubMed
    1. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99. 10.1136/annrheumdis-2019-216655 - DOI - PubMed
    1. Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis 2016;75:1479–85. 10.1136/annrheumdis-2015-208324 - DOI - PubMed
    1. Stoffer MA, Schoels MM, Smolen JS, et al. . Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 2016;75:16–22. 10.1136/annrheumdis-2015-207526 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data